Effects of Salmeterol on Walking Capacity in Patients With COPD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00525564|
Recruitment Status : Completed
First Posted : September 6, 2007
Last Update Posted : September 6, 2007
This study was designed to test the following hypothesis:
The acute changes in exercise tolerance during the endurance shuttle walk will be greater with salmeterol compared to placebo in patients with chronic obstructive pulmonary disease.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Drug: Placebo Drug: Salmeterol diskus inhalation powder||Phase 4|
Background: Little is known about the responsiveness of the endurance shuttle walking test (ESWT) to pharmacotherapy in patients with chronic obstructive pulmonary disease (COPD). This exercise testing modality needs to be further investigated because of its relevance for activity of daily living.
Objective: To evaluate, in patients with COPD, the responsiveness of the ESWT to detect improvement in walking performance after single dose of salmeterol.
Methods: In a randomised, double-blind, placebo-controlled, crossover study, 20 patients with COPD will perform, on two separate days, an ESWT at 80% of peak capacity, 2 hours after inhaling either a placebo or 50µg of salmeterol. Cardiorespiratory parameters will be monitored breath-by-breath during each walking test with a portable telemetric gas analyzer (Oxycom Mobile, Jaeger, Germany). Inspiratory capacities and Borg ratings for dyspnea were obtained every other minute throughout the tests.
Planned analysis. The main outcome will be endurance time. This variable will be compared between the two treatment arms using a paired t test. The time course of the cardiorespiratory parameters and dyspnea over time will be compared between the two exercise modalities. Comparisons will be done using a repeated measure design (ANOVA). Significance level will be set at a p value of 0.05.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||28 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Effects of Salmeterol on Walking Capacity in Patients With COPD|
|Study Start Date :||May 2006|
|Actual Study Completion Date :||October 2006|
Placebo Comparator: A
Placebo diskus inhalation powder
Active Comparator: B
Salmeterol diskus powder
Drug: Salmeterol diskus inhalation powder
50 micrograms twice a day
Other Name: Serevent
- Endurance time during an endurance shuttle walk [ Time Frame: acute response (2.5 hours) following the administration of the active and comparison drug ]
- Dyspnea during endurance shuttle walk [ Time Frame: acute response following the administration of the study medication ]
- cardio-respiratory responses during an endurance shutlle walk [ Time Frame: acute response following the administration of the study medication ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00525564
|Quebec City, Quebec, Canada, G1V 4G5|
|Principal Investigator:||François Maltais, MD||Laval University|